Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium

  • Luckett, Emma S.
  • Abakkouy, Yasmina
  • Lorenzini, Luigi
  • Collij, Lyduine E.
  • Vállez García, David
  • Visser, Pieter Jelle
  • den Braber, Anouk
  • Ritchie, Craig
  • Boada, Mercè
  • Genius, Patricia
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Vandenberghe, Rik
  • Barkhof, Frederik
  • Cleynen, Isabelle
  • AMYPAD Consortium
Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and EFPIA. F.B. and E.S.L. have received support for data curation and storage from the Alzheimer's Disease Data Initiative (ADDI; paid to institution). L.E.C. has acquired research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly), both paid to institution. L.E.C. is supported by the MSCA Postdoctoral fellowship (#101108819) and Alzheimer Association Research Fellowship (#23AARF-1029663) grants. N.V-T. receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, and grant PID2022-143106OA-I00 co-funded by the European Union FEDER). Additionally, N.V-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative, and grant 23S06083-001 funded by “la Caixa” Foundation and Barcelona City council. The F-PACK study was funded by the Stichting Alzheimer Onderzoek, Internal Funds KU Leuven, and Flemish Research Foundation (G0G1519N, G094418N), VLAIO (HBC.2019.2523, for R.V., Y.A., and I.C.). F.B. is supported by the NIHR biomedical research centre at UCLH.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes

  • Tranfa, Mario
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Lorenzini, Luigi
Background: The accumulation of amyloid-β1-42 (Aβ1-42) peptides and phosphorylated-Tau181 (p-Tau181) tangles from the preclinical stages of Alzheimer's disease (AD) has led to a biological definition of the disease. However, among Aβ1-42-positive individuals, cognitive decline onset varies, and some never develop symptoms. Genetic influences on molecular pathways and their interactions with proteinopathy may underlie this heterogeneity. Leveraging data from a large sample of cognitively intact older adults in the European Prevention of Alzheimer Dementia (EPAD) cohort, we examined how AD-related pathophysiological changes (i.e., Aβ1-42 and p-Tau181), polygenic pathways and their interaction are associated with WM micro- and macrostructural properties. Methods: We selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ1-42 and p-Tau181 measurements available, full genotyping, and structural and diffusion MRI. Polygenic risk scores (PRSs) were computed using 85 AD-related genetic variants. These were mapped to their corresponding genes and, after excluding those belonging to the APOE locus, clustered by function into six pathway-specific PRSs (i.e., immune activation, signal transduction, inflammation, lipid, amyloid, and clearance pathways). Diffusion MRIs were processed through the fixel-based analysis framework to derive fiber density (FD) and fiber cross-section (FC) metrics, which were averaged within WM tracts. Linear models assessed the effects of AD-related pathophysiological changes, global and pathway-specific PRSs, and their interactions on FD and FC at both the tract and fixel levels. Models were corrected for multiple comparisons. Results: P-Tau181 was primarily associated with greater FD. The lipid pathway was associated with greater FD and FC, with these effects predominantly occurring in the left hemisphere, consistent with evidence of hemispheric dominance. The clearance pathway moderated the effect of Aβ1-42 on FD, with a positive slope in A + compared to A- individuals. The immune activation pathway moderated the effect of p-Tau181 on FD, with a negative slope in T + compared to T- individuals. Conclusions: Pathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways., This work was funded by EU/EFPIA Innovative Medicines Initiative (IMI) grant 115736; Horizon 2020 grant 115952. ESL has received support for data curation and storage from the Alzheimer’s Disease Data Initiative (ADDI; paid to institution). LEC’s salary is supported by a MSCA postdoctoral fellowship research grant (101108819) and the Alzheimer Association Research Fellowship (grant 23AARF-1029663). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER; NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation. AA was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). JMW is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Society and Alzheimer's Research UK), the British Heart Foundation, The Fondation Leducq Network on Perivascular Spaces and the Row Fogo Centre for Research into Small Vessel Diseases. HJMMM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106). LL receives funding from the MSCA postdoctoral fellowship (#101204296).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes

  • Tranfa, Mario
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Lorenzini, Luigi
Background: The accumulation of amyloid-β1-42 (Aβ1-42) peptides and phosphorylated-Tau181 (p-Tau181) tangles from the preclinical stages of Alzheimer's disease (AD) has led to a biological definition of the disease. However, among Aβ1-42-positive individuals, cognitive decline onset varies, and some never develop symptoms. Genetic influences on molecular pathways and their interactions with proteinopathy may underlie this heterogeneity. Leveraging data from a large sample of cognitively intact older adults in the European Prevention of Alzheimer Dementia (EPAD) cohort, we examined how AD-related pathophysiological changes (i.e., Aβ1-42 and p-Tau181), polygenic pathways and their interaction are associated with WM micro- and macrostructural properties. Methods: We selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ1-42 and p-Tau181 measurements available, full genotyping, and structural and diffusion MRI. Polygenic risk scores (PRSs) were computed using 85 AD-related genetic variants. These were mapped to their corresponding genes and, after excluding those belonging to the APOE locus, clustered by function into six pathway-specific PRSs (i.e., immune activation, signal transduction, inflammation, lipid, amyloid, and clearance pathways). Diffusion MRIs were processed through the fixel-based analysis framework to derive fiber density (FD) and fiber cross-section (FC) metrics, which were averaged within WM tracts. Linear models assessed the effects of AD-related pathophysiological changes, global and pathway-specific PRSs, and their interactions on FD and FC at both the tract and fixel levels. Models were corrected for multiple comparisons. Results: P-Tau181 was primarily associated with greater FD. The lipid pathway was associated with greater FD and FC, with these effects predominantly occurring in the left hemisphere, consistent with evidence of hemispheric dominance. The clearance pathway moderated the effect of Aβ1-42 on FD, with a positive slope in A + compared to A- individuals. The immune activation pathway moderated the effect of p-Tau181 on FD, with a negative slope in T + compared to T- individuals. Conclusions: Pathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways., This work was funded by EU/EFPIA Innovative Medicines Initiative (IMI) grant 115736; Horizon 2020 grant 115952. ESL has received support for data curation and storage from the Alzheimer’s Disease Data Initiative (ADDI; paid to institution). LEC’s salary is supported by a MSCA postdoctoral fellowship research grant (101108819) and the Alzheimer Association Research Fellowship (grant 23AARF-1029663). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER; NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation. AA was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). JMW is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Society and Alzheimer's Research UK), the British Heart Foundation, The Fondation Leducq Network on Perivascular Spaces and the Row Fogo Centre for Research into Small Vessel Diseases. HJMMM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106). LL receives funding from the MSCA postdoctoral fellowship (#101204296).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium

  • Luckett, Emma S.
  • Abakkouy, Yasmina
  • Lorenzini, Luigi
  • Collij, Lyduine E.
  • Vállez García, David
  • Visser, Pieter Jelle
  • den Braber, Anouk
  • Ritchie, Craig
  • Boada, Mercè
  • Genius, Patricia
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Vandenberghe, Rik
  • Barkhof, Frederik
  • Cleynen, Isabelle
  • AMYPAD Consortium
Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., Introduction: We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition. Methods: Genetic data from five AMYPAD parent cohorts were harmonized, and PRS were computed for Alzheimer's disease (AD) susceptibility, cerebrospinal fluid (CSF) amyloid beta (Aβ)42, and CSF phosphorylated tau181. Cross-sectional amyloid (Centiloid [CL]) burden was available for all participants, and regression models determined if PRS were associated with CL burden. Results: After harmonization, data for 867 participants showed that high CL burden was most strongly predicted by CSF Aβ42 PRS compared to traditional AD susceptibility PRS. Discussion: This work emphasizes the importance of data harmonization and pooling of cohorts for large-powered studies. Findings suggest a genetic predisposition to amyloid pathology that may predispose individuals early in the AD continuum. This validates the potential use of PRS in clinical (trial) settings as a non-invasive tool to assess AD risk. Highlights: We developed a robust harmonization pipeline for multi-cohort genotype array data. Cerebrospinal fluid amyloid beta (Aβ)-specific polygenic risk scores (PRS) more strongly predicted global Aβ positron emission tomography burden than other PRS. Results suggest a strong genetic predisposition to early Aβ pathology. This work highlights the need for robust data harmonization and data pooling. This work also validates the potential use of PRS as a non-invasive tool to assess Alzheimer's disease risk., This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and EFPIA. F.B. and E.S.L. have received support for data curation and storage from the Alzheimer's Disease Data Initiative (ADDI; paid to institution). L.E.C. has acquired research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly), both paid to institution. L.E.C. is supported by the MSCA Postdoctoral fellowship (#101108819) and Alzheimer Association Research Fellowship (#23AARF-1029663) grants. N.V-T. receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, and grant PID2022-143106OA-I00 co-funded by the European Union FEDER). Additionally, N.V-T. is supported by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative, and grant 23S06083-001 funded by “la Caixa” Foundation and Barcelona City council. The F-PACK study was funded by the Stichting Alzheimer Onderzoek, Internal Funds KU Leuven, and Flemish Research Foundation (G0G1519N, G094418N), VLAIO (HBC.2019.2523, for R.V., Y.A., and I.C.). F.B. is supported by the NIHR biomedical research centre at UCLH.